1 / 10

Background & Objectives

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial.

rainer
Download Presentation

Background & Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S. Sabatine, MD, MPH, Kathleen A. Jablonski, PHD,Madeline Murguia Rice, PHD, Judith Hsia, MD, Ragnhild Wergeland, MT,Sverre Landaas, MD, PHD, Jean L. Rouleau, MD, FACC, Michael J. Domanski, MD, FACC, Christian Hall, MD, PHD, Marc A. Pfeffer, MD, PHD, FACC, Eugene Braunwald, MD, FACC, for the PEACE Investigators

  2. Background & Objectives • Background: The prognostic value of B-type natriuretic peptides (BNPs) in low-risk patients with stable coronary artery disease remains unclear. • Objectives: The purpose of this study was to assess 1) the association between BNP and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, 2) the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and 3) their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition.

  3. Methods • Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. • Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.

  4. Treatment assignment Age Gender Body mass index Ejection fraction <50% Estimated glomerular filtration rate Current smoking Total cholesterol C-reactive protein History of: hypertension or measured hypertension, myocardial infarction, diabetes, stroke, percutaneous coronary intervention, coronary artery bypass grafting, Use of: a beta-blocker, lipid-lowering drug, aspirin or an antiplatelet medication, or diuretic. MV Adjustment Outcomes were adjusted for:

  5. Association Between BNPs as Continuous Variables and CV Outcomes * Per 1 SD pg/ml in log BNP and log NT-proBNP, adjusted for randomization status

  6. NT-ProBNP and CV Death

  7. NT-ProBNP and Heart Failure

  8. NT-ProBNP and Stroke

  9. Multivariable Analysis of Association Between BNPs as Continuous Variables and CV Outcomes * Per 1 SD pg/ml in log BNP and NT-proBNP.

  10. Conclusion In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.

More Related